The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|January 24, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-01-2017
- Volume 12
- Issue 2
WuXi AppTec Acquires HD Biosciences
Author(s)Pharmaceutical Technology Editors
WuXi AppTech acquired HD Biosciences, a preclinical drug-discovery-focused CRO.
Advertisement
On Jan. 19, 2017 WuXi AppTec announced the acquisition of the biology-focused preclinical drug discovery contract research organization (CRO), HD Biosciences (HDB). After completion of the acquisition, HDB will become a wholly-owned subsidiary of WuXi. The company did not disclose the financial terms of the acquisition.
HBD is headquartered in Shanghai and has operating facilities in Beijing and San Diego, CA. HBD offers? plate-based pharmacology and screening capabilities, hit identification, lead discovery, and in vivo pharmacology, among other services. In a statement, WuXi said the acquisition will further strengthen its R&D capability from target validation to lead discovery and optimization, expanding WuXi's open-access enabling service platform.
Source:
Articles in this issue
over 9 years ago
Analytical Technologies for Bio/Pharmaceutical Developmentover 9 years ago
Connecting Contractors to a Pharma QMSover 9 years ago
Stars Seem Aligned for Healthy CDMO/CMO Marketover 9 years ago
New Drug Approvals Slump in 2016over 9 years ago
Ensuring Quality in Pharmaceutical Raw Materialsover 9 years ago
SGS Expands Extractables and Leachables Testingover 9 years ago
EAG Laboratories Adds Capabilities in Dermal Absorption Testingover 9 years ago
High Street Capital Acquires Avomeenover 9 years ago
Johnson Matthey Launches Online Catalyst StoreAdvertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5